Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies

Bibliographic Details
Main Authors:	Jeffrey Schlom, Claudia Palena, Sofia R Gameiro, Lucas A Horn, Kristin C Hicks, Christine M Minnar, Paul L Chariou
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-06-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/6/e004561.full

Similar Items

Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9.
by: Paul L Chariou, et al.
Published: (2024-01-01)

Immunomodulation of HDAC Inhibitor Entinostat Potentiates the Anticancer Effects of Radiation and PD-1 Blockade in the Murine Lewis Lung Carcinoma Model
by: Yeeun Kim, et al.
Published: (2022-12-01)

CaCO3 powder-mediated biomineralization of antigen nanosponges synergize with PD-1 blockade to potentiate anti-tumor immunity
by: Runping Su, et al.
Published: (2023-04-01)

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
by: Scott A. Tomlins, et al.
Published: (2023-02-01)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
by: Peng Liu, et al.
Published: (2022-12-01)

845 ABL503 (TJ-L14B), PD-L1×4–1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8+ T cells and synergizes with PD-1 blockade
by: Seung Hyuck Jeon, et al.
Published: (2023-11-01)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
by: Caroline Robert, et al.
Published: (2023-03-01)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
by: Christopher D. Zahm, et al.
Published: (2021-01-01)

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
by: Shaomeng Chen, et al.
Published: (2021-09-01)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
by: Man Wang, et al.
Published: (2023-02-01)

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
by: Ander Puyalto, et al.
Published: (2024-04-01)

Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
by: Alok Kumar, et al.
Published: (2020-03-01)

Polyoxazoline‐Based Nanovaccine Synergizes with Tumor‐Associated Macrophage Targeting and Anti‐PD‐1 Immunotherapy against Solid Tumors
by: Ana I. Matos, et al.
Published: (2023-09-01)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
by: Hiroo Katsuya, et al.
Published: (2023-11-01)

PD-1 and PD-L1 expression in rare lung tumors
by: Marton Gyulai, et al.
Published: (2023-05-01)

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment
by: Luís Costa, et al.
Published: (2022-07-01)

Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade
by: Jun Zhang, et al.
Published: (2022-06-01)

804 Anti-tumor effect of a novel Vβ TCR-targeting bifunctional agent in combination with anti-PD1 in checkpoint refractory murine lung cancer models
by: Jeffrey Schlom, et al.
Published: (2023-11-01)

Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis
by: Xin Guan, et al.
Published: (2022-05-01)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
by: Ana Bocanegra, et al.
Published: (2020-08-01)

Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade
by: S. K. Daniel, et al.
Published: (2024-03-01)

Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
by: Shuhang Wang, et al.
Published: (2022-01-01)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.
by: Janna Krueger, et al.
Published: (2021-01-01)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
by: David Escors, et al.
Published: (2022-10-01)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
by: Meng Chen, et al.
Published: (2022-11-01)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
by: Zihan Zhao, et al.
Published: (2023-03-01)

PD-1/CTLA-4 blockade leads to expansion of CD8+PD-1int TILs and results in tumor remission in experimental liver cancer
by: Sandra Bufe, et al.
Published: (2022-10-01)

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
by: Yunzhou Pu, et al.
Published: (2022-05-01)

Correction: Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade
Published: (2024-01-01)

The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring BRAF mutations: a systematic review and meta-analysis
by: Mauricio Fernando Silva Almeida Ribeiro, et al.
Published: (2022-10-01)

Biomarkers of response to PD-1 pathway blockade
by: Li, H, et al.
Published: (2022)

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
by: Jia-Wen Cui, et al.
Published: (2024-02-01)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
by: Nicholas J. Bevins, et al.
Published: (2022-11-01)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
by: Laura Jimbu, et al.
Published: (2021-03-01)

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes
by: Catarina Nascimento, et al.
Published: (2020-05-01)

Circulating Exhausted PD-1<sup>+</sup>CD39<sup>+</sup> Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
by: Carlos Martinez-Gomez, et al.
Published: (2022-07-01)

1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism
by: Chao Wang, et al.
Published: (2023-11-01)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
by: Yu Yuan, et al.
Published: (2021-02-01)

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy
by: Ali Razaghi, et al.
Published: (2023-08-01)

The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
by: Sajad Najafi, et al.
Published: (2023-05-01)